Evidence map›Paper›PMID 41646485›Full record

ArticleESMO gastrointestinal oncology2025

Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trends.

M F Ystgaard, T Å Myklebust, J Smeby, I K Larsen, T K Guren, E H Kure, K M Tveit, B Glimelius, M G Guren, J Hamfjord

Abstract read
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M F YstgaardDepartment of Oncology, Oslo University Hospital, Oslo.
T Å MyklebustDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo.
J SmebyDepartment of Oncology, Oslo University Hospital, Oslo.
I K LarsenDepartment of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo.
T K GurenDepartment of Oncology, Oslo University Hospital, Oslo.
E H KureDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo.
K M TveitDivision of Cancer Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
B GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala university, Uppsala, Sweden.
M G GurenDepartment of Oncology, Oslo University Hospital, Oslo.
J HamfjordDepartment of Oncology, Oslo University Hospital, Oslo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The overall incidence of colorectal cancer (CRC) has decreased or stabilized in most high-income countries, but an increase is observed in adults <50 years of age, termed early-onset colorectal cancer (EOCRC). Materials and methods: We conducted a nationwide registry-based study to provide up-to-date incidence patterns of EOCRC, with an emphasis on age-specific differences in tumor site and morphology. We extracted data from the Cancer Registry of Norway, with completeness estimated to be >99%. We calculated age-standardized incidence rates and used joinpoint regression to provide annual percentage change (APC) and average annual percentage change (AAPC). National screening started in Norway in 2022; hence, this study is on a largely screening-naive population. Results: There were 107 523 cases of CRC diagnosed between 1993 and 2022 eligible for analysis. The incidence of EOCRC (20-49 years) increased by 66% (AAPC 1.3), caused by left-sided colon and rectal cancers. The age group 50-74 years had a stable overall incidence (AAPC -0.2). In the age group ≥75 years, an increased incidence (AAPC 0.8) was observed, mainly by right-sided colon cancer, which increased until 2016 (APC 2.5), followed by a decrease (APC -0.9). EOCRC adenocarcinomas increased by 77% (AAPC 1.4). Neuroendocrine neoplasms were rare (1.4%), but increased in all age groups (AAPC 4.2). EOCRC showed a significantly higher proportion of distant metastases at time of diagnosis compared with the age group ≥75 years (28.6% versus 18.2%, Conclusions: We observed a sustained increase in EOCRC, caused by left-sided colon and rectal cancers. Unlike countries with established screening programs, the incidence of the age group >50 years remained stable or increased, but declined in recent years.

Indexed as

adenocarcinomacolorectal cancerearly-onsetincidenceneuroendocrineprimary tumor location

Identifiers

PMID41646485
PMCPMC12836505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.